Downregulation of a novel long noncoding RNA TRPM2-AS promotes apoptosis in non–small cell lung cancer

Huang, Cheng; Qin, Yingzhi; Liu, Huan; Liang, Ning; Chen, Yeye; Ma, Dongjie; Han, Zhijun; Xu, Xiaohui; Zhou, Xin; He, Jia; Li, Shanqing

doi:10.1177/1010428317691191

Cited by 35 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TRPM2-AS is an antisense lncRNA mapped to 44 658 901-44 669 874 position of TRPM2 gene (Orfanelli et al, 2008). It was demonstrated to be an oncogene for non-small-cell lung cancer, prostate cancer, and hepatocellular carcinoma (Huang et al, 2017;Orfanelli et al, 2015;Xu et al, 2018). However, its effects in gliomas are unknown.…”

Section: Discussionmentioning

confidence: 99%

“…Studies found the presence of TRPM2‐AS activation in many carcinomas, such as melanoma (Orfanelli et al, ), lung cancer (Huang et al, ), and prostate cancer (Mouraviev et al, ). Downregulation of TRPM2‐AS prompted apoptosis and interfered with the cisplatin resistance in non‐small‐cell lung cancer (Huang et al, ; Ma et al, ). However, its roles in cancer metastasis and its roles in gliomas remain unknown.…”

Section: Introductionmentioning

confidence: 99%

“…TRPM2-AS is a lncRNA transcripted from the antisense chain of TRPM2, a voltage-independent calcium-permeable cation channel belonging to the transient receptor potential subfamily (Clapham, 2003;Orfanelli et al, 2008). Studies found the presence of TRPM2-AS activation in many carcinomas, such as melanoma (Orfanelli et al, 2008), lung cancer (Huang et al, 2017), and prostate cancer (Mouraviev et al, 2016). Downregulation of TRPM2-AS prompted apoptosis and interfered with the cisplatin resistance in non-smallcell lung cancer (Huang et al, 2017;Ma et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

TRPM2‐AS inhibits the growth, migration, and invasion of gliomas through JNK, c‐Jun, and RGS4

Bao

Szeto

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Gliomas are a group of brain cancers with high mortality and morbidity. Understanding the molecular mechanisms is important for the prevention or treatment of gliomas. The present study was to investigate the effects and mechanisms of long noncoding RNA TRPM2-AS in gliomas proliferation, migration, and invasion. We first compared the levels of TRPM2-AS in 111 patients with glioma to that of the normal control group by a quantitative polymerase chain reaction. The results indicated a significant increase of TRPM2-AS in patients with glioma (2.43 folds of control, p = .0135). MTT methods, wound healing assays, transwell analysis, and clone formation analysis indicated the overexpression of TRPM2-AS promoted the proliferation, migration, and invasion of U251 and U87 cells, while downregulation of TRPM2-AS inhibited the cell proliferation, migration, and invasion significantly (p < .05). To further uncover the mechanisms, bioinformatics analysis was conducted on the expression profiles, GSE40687 and GSE4290, from the Gene Expression Omnibus database. One hundred fifty-six genes were differentially expressed in both datasets (FC > 2.0; p = .05). Among these differentially expressed genes, the level of RGS4 messenger RNA was drastically regulated by TRPM2-AS. Further western-blot analysis indicated the increase of RGS4 protein expression and decrease of p-JNK/ JNK and p-c-Jun/c-Jun ratio after TRPM2-AS overexpression. On the other hand, inhibition of TRPM2-AS by small interfering RNA suppressed the expression of RGS4 and promoted the ratios of p-JNK/JNK and p-c-Jun/c-Jun. The present work indicated the mechanisms of the participation of TRPM2-AS in the progression of gliomas might, at least partly, be related to JNK, c-Jun, and RGS4. Our work provided new insights into the underlying mechanisms of glioma cellular functions. K E Y W O R D S glioma, lncRNA, RGS4, TRPM2-AS *Mei-Hua Bao and Qiao-Li Lv contributed equally to this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

TRPM2‐AS inhibits the growth, migration, and invasion of gliomas through JNK, c‐Jun, and RGS4

Bao

Szeto

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…lncRNA TRPM2-AS, which is an antisense lncRNA of TRPM2, is 875 nt in length and located in the chr21q22.3 locus [13]. TRPM2-AS was first studied in prostate cancer [13] and then studied in the context of non-small cell lung cancer (NSCLC), where it was found to be related to the survival of NSCLC patients and chemoresistance in NSCLC [14,15]. However, until now, the role of lncRNA TRPM2-AS in HCC has not been studied.…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA TRPM2-AS as a potential biomarker for hepatocellular carcinoma

Huang

Zhang

et al. 2017

Ir J Med Sci

View full text Add to dashboard Cite

Background There is increasing evidence that long noncoding RNAs are involved in hepatocellular carcinoma (HCC) tumorigenesis. The expression level of TRPM2-AS in HCC and its clinical association remain poorly defined. Method qRT-PCR was performed to detect the expression of TRPM2-AS in 108 HCC patients. The correlations between TRPM2-AS expression and clinicopathological factors and prognosis were evaluated. The inference of TRPM2-AS to the proliferation and apoptosis of HCC cells was detected. Aims The aim of our study was to explore the expression of TRPM2-AS in hepatocellular carcinoma (HCC) and the relation with prognosis and clinical features. Results The expression of TRPM2-AS was higher in most HCC tissues and was significantly correlated with tumor size, AJCC stage, tumor differentiation, and the prognosis of HCC patients. Interfering TRPM2-AS expression using siRNA significantly inhibited cell proliferation and promoted cell apoptosis in two HCC cell lines. Conclusion Long non-coding RNA TRPM2-AS is upregulated in HCC and represents a new biomarker for HCC and the inhibition of TRPM2-AS promotes apoptosis in HCC cells in vitro.

show abstract

“…10,11 TRPM2-AS locates at human chr21q22.3, and consists of 875 nucleotides with three exons in the translation template. 12 TRPM2-AS has been revealed to be upregulated and involved in the progression of melanoma, 12 non-small cell lung cancer, 13,14 hepatocellular carcinoma, 15 and prostate cancer. [16][17][18] The expression status and function of TRPM2-AS were still in osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Transient receptor potential melastatin 2–antisense RNA is overexpresed in osteosarcoma and regulates cell proliferation and apoptosis

Geng

Ming

2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Accumulating evidence suggested that transient receptor potential melastatin 2–antisense RNA (TRPM2‐AS) played crucial roles in the progression of human cancers. However, the role of TRPM2‐AS was still unknown in osteosarcoma. The aim of this study was to explore the clinical significance of TRPM2‐AS in osteosarcoma patients, and determine the role of TRPM2‐AS on osteosarcoma cell proliferation and apoptosis. In our results, we identified a novel oncogenic long noncoding RNA TRPM2‐AS, which was overexpressed in osteosarcoma tissues and cells, and correlated with advanced Enneking stage, large tumor size and high histological grade in osteosarcoma cases. Survival analysis indicated that osteosarcoma patients with high TRPM2‐AS expression had an obviously shorter overall survival time than those with low TRPM2‐AS expression. Loss‐of‐function studies suggested that suppression of TRPM2‐AS expression inhibited osteosarcoma cell proliferation and induced cell apoptosis through upregulating cleaved caspase‐3 and cleaved caspase‐9 expression. In conclusion, TRPM2‐AS acts as an oncogenic long noncoding RNA and predicts poor prognosis in osteosarcoma.

show abstract

Downregulation of a novel long noncoding RNA TRPM2-AS promotes apoptosis in non–small cell lung cancer

Cited by 35 publications

References 26 publications

TRPM2‐AS inhibits the growth, migration, and invasion of gliomas through JNK, c‐Jun, and RGS4

TRPM2‐AS inhibits the growth, migration, and invasion of gliomas through JNK, c‐Jun, and RGS4

Long non-coding RNA TRPM2-AS as a potential biomarker for hepatocellular carcinoma

Transient receptor potential melastatin 2–antisense RNA is overexpresed in osteosarcoma and regulates cell proliferation and apoptosis

Contact Info

Product

Resources

About